26.43

0.80% 0.21

Pre-market: 26.47 0.04 +0.15%

Zymeworks Inc. (ZYME)

Overview News Price History Option Chain Discussions Forecast

Zymeworks Inc. stock is traded at $26.43, with a volume of 441.70K. It is up +0.80% in the last 24 hours and up +45.54% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Previous Close:

$26.22

Open:

$26.18

24h Volume:

441.70K

Relative Volume:

0.40

Market Cap:

$1.99B

Revenue:

$122.87M

Net Income/Loss:

$-73.68M

P/E Ratio:

-26.96

EPS:

-0.9803

Net Cash Flow:

$-39.27M

1W Performance:

-3.29%

1M Performance:

+45.54%

6M Performance:

+116.64%

1Y Performance:

+87.31%

1-Day Range:

$25.91

$26.96

1-Week Range:

$24.83

$27.69

52-Week Range:

$9.03

$28.49

Zymeworks Inc. Stock (ZYME) Company Profile

Name

Zymeworks Inc.

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

604-678-1388

Address

1385 West 8th Avenue, Suite 540, Vancouver, BC

Employee

170

Twitter

@ZymeworksInc

Next Earnings Date

2024-10-31

Latest SEC Filings

ZYME's Discussions on Twitter

Compare ZYME with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZYME Zymeworks Inc.	26.43	1.98B	122.87M	-73.68M	-39.27M	-0.9803
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-24-25	Resumed	Wells Fargo	Equal Weight
Oct-14-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-10-25	Initiated	B. Riley Securities	Buy
May-20-25	Initiated	TD Cowen	Buy
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-21-23	Resumed	Wells Fargo	Overweight
Jan-04-23	Reiterated	H.C. Wainwright	Neutral
Dec-20-22	Upgrade	Jefferies	Hold → Buy
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-04-22	Resumed	Wells Fargo	Overweight
May-05-22	Upgrade	Guggenheim	Neutral → Buy
Mar-15-22	Initiated	Evercore ISI	Outperform
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold
Mar-31-21	Initiated	Credit Suisse	Outperform
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-08-21	Resumed	H.C. Wainwright	Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-06-20	Initiated	SVB Leerink	Outperform
Jan-10-20	Initiated	Wolfe Research	Outperform
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy
Nov-20-19	Initiated	Guggenheim	Buy
Sep-30-19	Upgrade	Raymond James	Outperform → Strong Buy
Aug-30-19	Initiated	Stifel	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
May-11-18	Upgrade	Barclays	Underweight → Equal Weight
Mar-19-18	Initiated	Raymond James	Outperform

View All

Zymeworks Inc. Stock (ZYME) Latest News

02:06 AM

Is Zymeworks Inc. (ZA8) stock cheap vs fundamentalsPortfolio Value Report & Long Hold Capital Preservation Tips - Newser

02:06 AM

Dec 04, 2025

How higher bond yields impact Zymeworks Inc. (ZA8) stock2025 Buyback Activity & Daily Profit Focused Screening - Newser

Dec 04, 2025

What technical patterns form on Zymeworks Inc. (ZA8) stock chartsWeekly Gains Summary & Short-Term Swing Trade Alerts - Newser

Dec 04, 2025

Is Zymeworks Inc. (ZA8) stock considered safe havenInsider Selling & AI Powered Market Trend Analysis - Newser

Dec 04, 2025

Will Zymeworks Inc. (ZA8) stock maintain strong growth2025 Earnings Impact & Safe Capital Allocation Plans - Newser

Dec 04, 2025

Dec 03, 2025

Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN

Dec 03, 2025

Citizens Initiates Coverage of Zymeworks (ZYME) with Market Outperform Recommendation - Nasdaq

Dec 03, 2025

How Zymeworks Inc. (ZA8) stock performs in volatility spikesJuly 2025 Gainers & Verified Technical Signals - Newser

Dec 03, 2025

Dec 02, 2025

Zymeworks Announces Participation in Upcoming Conferences - The Manila Times

Dec 02, 2025

Zymeworks Inc. Announces Participation in ASCO GI and J.P. Morgan Healthcare Conference, Highlighting Advances in HER2-Driven Gastrointestinal Cancers and Novel Drug Developments - Quiver Quantitative

Dec 02, 2025

Is Zymeworks Inc. (ZA8) stock supported by strong fundamentalsAnalyst Upgrade & Accurate Intraday Trade Tips - Newser

Dec 02, 2025

Dec 01, 2025

Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Zymeworks Inc. $ZYME - MarketBeat

Dec 01, 2025

Nov 30, 2025

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - MSN

Nov 30, 2025

Nov 29, 2025

Is Zymeworks Inc a good long term investmentMarket Capitalization Trends & Join a Community of Smart Investors - earlytimes.in

Nov 29, 2025